Rising prostate-specific antigen after primary prostate cancer therapy
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology,General Medicine
Link
http://www.nature.com/articles/ncpuro0145.pdf
Reference65 articles.
1. Khan MA et al. (2003) Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 62: 86–91; discussion 91–92
2. Djavan B et al. (2003) PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. Eur Urol 43: 12–27
3. Polascik TJ et al. (1999) Prostate specific antigen: a decade of discovery—what we have learned and where we are going. J Urol 162: 293–306
4. Ward JF et al. (2003) The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170: 1872–1876
5. Pound CR et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591–1597
Cited by 80 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Prostatectomy Bed Image-guided Dose-escalated Salvage Radiotherapy (SPIDER): An International Multicenter Retrospective Study;European Urology Oncology;2023-08
2. (18F)-PSMA-1007PET/CT in patients with biochemical recurrence after radical prostatectomy: Diagnostic performance and impact on treatment management;Research in Diagnostic and Interventional Imaging;2023-03
3. Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial;International Journal of Radiation Oncology*Biology*Physics;2022-05
4. Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol;BMC Cancer;2022-04-15
5. Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial;European Urology;2021-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3